If you’ve been prescribed an antidepressant, or you’re weighing two that a provider mentioned, the names can blur together. SSRI, SNRI: one letter apart, and it isn’t obvious what that letter changes. Both are common, well-studied families of antidepressants, and the main difference comes down to which chemical messengers in the brain each one acts on. Here’s the plain-language version, and what it means when you and a provider are choosing between them.
The short answer: one brain chemical, or two
The clearest way to see the difference between an SSRI and an SNRI is to look at what each one does in the brain. SSRIs, short for selective serotonin reuptake inhibitors, raise the level of serotonin, one of the chemical messengers nerve cells use to communicate. They do this by blocking reuptake, the process that normally clears serotonin away, so more of it stays available.[3][2] An SNRI, a serotonin-norepinephrine reuptake inhibitor, works the same way on serotonin but acts on a second messenger as well: norepinephrine.[2][4] That’s the whole distinction in a sentence. An SSRI works on one chemical; an SNRI works on two.[3]
You’ll recognize most of these by their generic names. Common SSRIs include sertraline, escitalopram, fluoxetine, paroxetine, and citalopram.[3][2] Common SNRIs include venlafaxine, duloxetine, and desvenlafaxine.[2][4]
Are SNRIs stronger than SSRIs?
This is the most common assumption: two chemicals must beat one. The evidence doesn’t bear that out. The largest comparison to date, a 2018 analysis of more than 500 trials and over 116,000 people, found that every antidepressant studied worked better than a placebo, and that the differences between the individual drugs were modest.[6] The most effective options spanned several classes, with both SSRIs and an SNRI among them, and no single class came out on top.[6]
A separate review that compared the two classes head to head did find a slightly higher remission rate for SNRIs, but the authors were clear that the difference, while statistically measurable, was not clinically meaningful.[7] That’s much of why SSRIs are usually tried first. Not because SNRIs are weaker, but because SSRIs tend to be just as effective for most people and a little easier to tolerate.[3]
Why a provider might choose one over the other
If the two are so close for depression, why pick an SNRI at all? Often it comes down to what else is going on. Both classes are also used to treat anxiety disorders, so for many people either one is a reasonable starting point.[1][3] The clearest reason to reach for a specific SNRI is pain. Duloxetine is approved not only for depression and anxiety but also for fibromyalgia, diabetic nerve pain, and ongoing musculoskeletal pain, conditions an SSRI isn’t used to treat.[5] Its action on norepinephrine is part of why it can help with pain as well as mood.[5]
Beyond that, the choice is individual. Your history, your other health conditions, the side effects you most want to avoid, and how you’ve responded to a medication before all factor in. People respond differently to the same drug, and it sometimes takes more than one try to find the right fit.[1] That’s a decision to make with your prescriber, and it’s a core part of ongoing medication management.
Side effects: what’s shared and what differs
Because both classes raise serotonin, they share many of the same possible side effects. Nausea or other stomach upset, changes in sleep, dizziness, headache, and sexual side effects can show up with either one.[3][4] Most are mild and tend to ease with time as your body adjusts.[1]
The main difference shows up with the extra messenger. By acting on norepinephrine, SNRIs can nudge blood pressure up, which is why a provider may check yours while you’re taking one.[4] It’s a manageable thing to keep an eye on, and part of why follow-up visits matter.
Stopping either one: why you taper
One thing holds for both classes: you don’t stop them suddenly. Coming off an antidepressant too quickly can bring on discontinuation symptoms, things like dizziness, headache, nausea, trouble sleeping, and irritability, which is why the dose is usually lowered gradually under a provider’s guidance.[1][8]
This is also where “which one is harder to come off of” has a real answer, and it isn’t about the class. Medications that leave the body quickly, those with a shorter half-life, tend to cause more discontinuation symptoms; the SNRI venlafaxine and the SSRI paroxetine are both examples.[8][4] So it’s the specific medication and its half-life that matter, not the class. Either way, when the time comes to stop, a gradual taper planned with your prescriber is the safe approach.[1]
Key takeaways
- SSRIs raise serotonin; SNRIs raise serotonin and norepinephrine. That second chemical is the whole difference.
- SNRIs aren’t “stronger.” Large comparisons show the two classes are similarly effective, and SSRIs are usually tried first because they’re a little easier to tolerate.
- A provider may choose an SNRI when there’s also chronic or nerve pain; duloxetine is approved for several pain conditions an SSRI isn’t.
- The classes share many side effects (nausea, sleep changes, dizziness, sexual side effects); the main difference is that SNRIs can raise blood pressure.
- Neither should be stopped abruptly. How hard it is to come off depends on the medication’s half-life, not its class, so taper with your prescriber.
Two acronyms that look almost the same describe a real but narrow difference, and for most people it matters less than the names suggest. If you’re trying to understand your own medication, or wondering whether a different one might fit better, that’s a good conversation to bring to your provider. You can read more in our complete guide to psychiatric medication management, see what to expect on the related question of how long an antidepressant takes to work, or request an appointment with our team whenever you’re ready.
- Mental Health Medications · National Institute of Mental Health (2023)
- Antidepressants · StatPearls, NIH National Library of Medicine (2023)
- Selective Serotonin Reuptake Inhibitors · StatPearls, NIH National Library of Medicine (2023)
- Venlafaxine · StatPearls, NIH National Library of Medicine (2024)
- Duloxetine · StatPearls, NIH National Library of Medicine (2023)
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder · Cipriani et al., The Lancet (2018)
- Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials · Machado & Einarson, Journal of Clinical Pharmacy and Therapeutics (2010)
- A review of the management of antidepressant discontinuation symptoms · Therapeutic Advances in Psychopharmacology (2015)
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with any questions about your health or a medical condition.